Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Selina Shah

Sports Medicine Walnut Creek, CA Medical Doctor

NPI 1205995958 CMS profile 995871

2255 Ygnacio Valley Rd Ste V, Walnut Creek, CA 94598

Open in the dashboard

General payments

$11,494

92 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Selina Shah of Walnut Creek, CA is reported in the CMS Open Payments database as having received $11,494 across 92 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $183 7
2024 General $26 1
2023 General $233 8
2022 General $2,926 16
2021 General $4,224 24
2020 General $3,122 14
2019 General $780 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Selina Shah
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Selina Shah were reported at $183. Among 132 Sports Medicine profiles paid that year, the median was $99 and the middle half received between $33 and $256.

Show as a table
Year Selina Shah Sports Medicine median Middle half National median
2019 $780 $131 $46–$324 $163
2020 $3,122 $96 $34–$276 $114
2021 $4,224 $120 $33–$421 $132
2022 $2,926 $107 $31–$274 $149
2023 $233 $63 $25–$180 $160
2024 $26 $104 $28–$282 $164
2025 $183 $99 $33–$256 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Djo, LLC $9,900 31 payments
  2. Bioventus LLC $433 14 payments
  3. Fidia Pharma USA Inc. $359 16 payments
  4. Flexion Therapeutics, Inc. $219 8 payments
  5. HydroCision, Inc. $124 4 payments
  6. Pacira Pharmaceuticals Incorporated $123 5 payments
  7. Avanos Medical $68 3 payments
  8. Ossur Americas., Inc $60 2 payments
  9. Horizon Therapeutics plc $48 3 payments
  10. Tenex Health Inc. $45 1 payment
  11. Other $115 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $9,900 31 payments
  2. Food and Beverage $1,594 61 payments
Products named General payments · program years 2019–2025
  1. AIRCAST Bracing & Supports $3,900 13 payments
  2. PROCARE Bracing & Supports $3,900 13 payments
  3. PROCARE $2,700 7 payments
  4. HYMOVIS $325 14 payments
  5. Zilretta $219 8 payments
  6. GELSYN-3 $191 6 payments
  7. TRILURON $167 6 payments
  8. TenJet $124 4 payments
  9. SpineJet $124 4 payments
  10. AlloJet $124 4 payments
  11. Other $727 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

142

Median for Sports Medicine: 144

Drug cost

$888

Median for Sports Medicine: $1,027

Branded share of claims

0%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 31 $325
Gabapentin Generic 21 $220
Meloxicam Generic 60 $148
Celecoxib Generic 12 $117
Naproxen Generic 18 $78

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$254,872

Of which drugs: $66,230

Medicare patients

340

Average age 75

Services billed

7,281

236 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 46%
Osteoporosis 26%
Ischemic heart disease 16%
Cancer 16%
Depression 13%
Diabetes 12%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 66 4,896 $65,731
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 102 647 $499

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

92 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record